BiotechTube

Pembrolizumab plus Lenvatinib

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angiosarcoma of Skin

Conditions

Angiosarcoma of Skin, Angiosarcoma Metastatic

Trial Timeline

Dec 1, 2024 → Nov 30, 2029

NCT ID
NCT06673628

About Pembrolizumab plus Lenvatinib

Pembrolizumab plus Lenvatinib is a phase 2 stage product being developed by Merck for Angiosarcoma of Skin. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06673628. Target conditions include Angiosarcoma of Skin, Angiosarcoma Metastatic.

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06673628Phase 2Recruiting

Competing Products

6 competing products in Angiosarcoma of Skin

See all competitors
ProductCompanyStageHype Score
EribulinEisaiPhase 2
39
Avelumab + PaclitaxelMerckPhase 2
31
Pazopanib + PaclitaxelNovartisPhase 2
27
regorafenibBayerPhase 2
32
Vusolimogene Oderparepvec (VO) + PembrolizumabReplimunePhase 2
36
AGEN2034 + AGEN1884AgenusPhase 2
17